What if the complex journey of turning a groundbreaking biologic into a life-saving therapy could be transformed into a streamlined, efficient process? In a world where biopharmaceutical development faces unprecedented challenges, a powerful collaboration between Rentschler Biopharma and Coriolis
Regulated bioprocesses rise or fall on the quiet details—additives, excipients, and media choices that shape every run and either unlock reproducibility or invite costly variability when scale-up and compliance converge. In that context, high‑purity methylcellulose has reemerged as a practical
What if the very speed that delivered lifesaving vaccines also cemented a single-technology playbook that looks nimble in peacetime but brittle under pressure when the next pathogen demands different strengths and a steadier supply chain than speed alone can provide? The COVID-19 race crowned mRNA
Rising failure rates for single-mechanism therapies in heterogeneous solid tumors have pushed oncology beyond single-target tinkering and into platform-centric thinking that prizes modularity, combinability, and consistent manufacturability across programs. In this shift, antibody-drug conjugates
The drumbeat behind next-generation biologics has been unmistakable, yet the loudest voices in today’s pipelines keep returning to a sobering reality: delivery is not polish at the finish line, it is the race itself, where fragile molecules, strict dosing windows, and hard-to-reach tissues force
In an era where supply chain resilience and access to life-saving therapies dominate healthcare discussions, AstraZeneca's announcement of a $2 billion investment in Maryland facilities has captured significant attention, raising critical questions about domestic production. This ambitious
